Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 969 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Endocrine-therapy Clear all
Recruiting Not applicable Interventional

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

NCT07629206
View directory record Official record
Conditions
Low-Risk, Early Stage Breast Cancer
Interventions
Cryoablation
Device
Lead sponsor
IceCure Medical Ltd.
Industry
Eligibility
70 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
Glendale, California • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 12, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Results available

Vidaza to Restore Hormone Thx Prostate

NCT00384839
View directory record Official record
Conditions
Prostate Cancer
Interventions
azacitidine for injectable suspension
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
13
States / cities
Denver, Colorado • Ocoee, Florida • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 12, 2026, 7:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mild Cognitive Impairment in Breast Cancer Patients

NCT01949376
View directory record Official record
Conditions
Breast Cancer, Cognitive Impairment
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 12, 2026, 7:38 PM EDT
Completed No phase listed Observational

Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index

NCT01701050
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Blood collection
Other
Lead sponsor
Janssen Diagnostics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Phoenix, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 12, 2026, 7:38 PM EDT
Completed Phase 3 Interventional

The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

NCT00406926
View directory record Official record
Conditions
Turner Syndrome
Interventions
Somatropin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
9 Months to 4 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2006 · Synced Sep 12, 2026, 7:38 PM EDT
Suspended Not applicable Interventional

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

NCT04419779
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Device
Lead sponsor
Fractyl Health Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
51
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 12, 2026, 7:38 PM EDT
Recruiting Not applicable Interventional

Cardiometabolic Screening Program

NCT05386719
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer
Interventions
Prescreening, Screening and Enrollment, Baseline, Interpret BMI, Interpret HbA1c, Interpret lipid panel and assess other risk factors, Assess 10 year risk of cardiovascular event, Recommendations, Follow-Up
Other · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 12, 2026, 7:38 PM EDT
Completed Not applicable Interventional

Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial

NCT02256670
View directory record Official record
Conditions
Breast Cancer
Interventions
Text Message Application
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 12, 2026, 7:38 PM EDT
Completed Phase 2 Interventional

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer

NCT02676986
View directory record Official record
Conditions
Primary Breast Cancer ER+ve, Primary Breast Cancer AR+ve TNBN
Interventions
Enzalutamide, Exemestane
Drug
Lead sponsor
Queen Mary University of London
Other
Eligibility
18 Years and older · Female only
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 12, 2026, 7:38 PM EDT
Terminated Not applicable Interventional

The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer

NCT01351844
View directory record Official record
Conditions
Breast Cancer, Arthralgia
Interventions
Education and exercise intervention, Education and General Exercise
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 12, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Prevention of Obesity in Women Via Estradiol Regulation

NCT00687739
View directory record Official record
Conditions
Obesity
Interventions
leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 12, 2026, 7:38 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211
View directory record Official record
Conditions
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 12, 2026, 7:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00566813
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplant, Islet Cell Transplant plus
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 12, 2026, 7:38 PM EDT
Terminated Phase 1 Interventional Results available

Growth Hormone Therapy for Wasting in Cystic Fibrosis

NCT00803179
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nutropin AQ
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 12, 2026, 7:38 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Endocrine Therapy (ET)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 12, 2026, 7:38 PM EDT
Suspended Phase 3 Interventional

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

NCT06671912
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
728
States / cities
Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 12, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Results available

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

NCT00118092
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
tanespimycin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 12, 2026, 7:38 PM EDT
Active, not recruiting Phase 2 Interventional

The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

NCT02653755
View directory record Official record
Conditions
Breast Cancer Radiation
Interventions
Prosigna
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 12, 2026, 7:38 PM EDT
Completed Not applicable Interventional

Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer

NCT03949270
View directory record Official record
Conditions
Breast Cancer, Adherence, Medication, Side Effect
Interventions
BETA-Text text messaging intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 12, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Adjuvant endocrine therapy, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 12, 2026, 7:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Women's Health Initiative Memory Study (The WHIMS Study)

NCT00685009
View directory record Official record
Conditions
Dementia Syndromes
Interventions
Estrogen hormone therapy, Estrogen plus progesterone hormone therapy, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
65 Years to 79 Years · Female only
Enrollment
7,525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 12, 2026, 7:38 PM EDT
Recruiting Not applicable Interventional

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

NCT06106477
View directory record Official record
Conditions
Breast Cancer
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 12, 2026, 7:38 PM EDT
Not listed Not applicable Interventional

A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer

NCT04086875
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive Tumor, Progesterone Receptor Positive Tumor, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Focus Group, Text Message, Best Practice, Questionnaire Administration
Behavioral · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Sewell, New Jersey • Abington, Pennsylvania • Doylestown, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2024 · Synced Sep 12, 2026, 7:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Multi-omic Approach to Evaluate and Characterize the Polycystic Ovary Syndrome (PCOS) Phenotype

NCT04981275
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
No intervention study
Other
Lead sponsor
Onegevity Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 12, 2026, 7:38 PM EDT